• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

F2G

edit

F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.

Recent Milestones

edit

• 
  F2G received $30M in Venture Round funding. (9/5/12)
  Posted 9/5/12 at 9:11pm via fiercebiotech.com
• 
  F2G received $11.8M (£6.3M) in Venture Round funding. (8/18/08)
  Posted 6/22/09 at 11:37pm via f2g.com
• 
  F2G added Shane Kelly as Chief Executive Officer.
  Posted 6/22/09 at 11:25pm
• 
  F2G added Thomas Tscherning as Non Executive Director.
  Posted 6/22/09 at 11:25pm

Videos

Screenshots

edit

Above: F2G
Uploaded: 6/23/09

Sources

1. F2G Ltd completes £6.3million financing round to fund pre-clinical and clinical development (f2g.com) [edit]
2. F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds (fiercebiotech.com) [edit]